HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression
Cancer Immunology, Immunotherapy · Published 2026-07-17 · DOI 10.1007/s00262-026-04491-z · PMID: 42469430
Free full text
Authors (8)
Yan Chen, Feng Zeng, Shan Liao, Yan Lei, Qian He, Yanhong Zhou, Yanling Li, Chen Long
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Chen, Y., Zeng, F., Liao, S., et al. (2026). HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04491-z
Related articles
- Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis · Cancer Immunology, Immunotherapy · 2026 · Same journal
- Integrative analysis of small cell carcinoma of the uterine cervix reveals its heterogeneity and provides novel predictive markers · Cancer Immunology, Immunotherapy · 2026 · Same journal
- The microbiota–lymphocyte protective axis (MLPA): a novel paradigm for overcoming radiation-induced lymphopenia (RIL) and potentiating the efficacy of tumor immuno-combination therapy · Cancer Immunology, Immunotherapy · 2026 · Same journal